Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo enters lice market

This article was originally published in The Tan Sheet

Executive Summary

The Allegan, Mich.-based private labeler enters an agreement March 7 to expand its offerings into a new category by paying $12 mil. in cash for Qualis's store-brand pediculicide products in a transaction the firms expect to close around June 30. In a release, Perrigo President and CEO Joe Papa says the acquisition will bring "a range of products that fits nicely within our Consumer Healthcare business portfolio." The firm says adding Des Moines, Iowa-based Qualis's OTC product formulations similar to the Rid and Nix brands should increase its sales by $10 mil. annually...

You may also be interested in...



Perrigo closes Qualis deal

Perrigo completes its acquisition of Des Moines, Iowa-based store-brand pediculicide manufacturer Qualis for $12 mil. cash, the firm announces July 11. The deal, initially announced in March, gives the private labeler five OTC products equivalent to Bayer's Rid and Insight Pharmaceuticals' Nix lice products, which are expected to add more than $10 mil. to annual sales, the Allegan, Mich.-based firm says (1"The Tan Sheet" March 12, 2007, In Brief)...

IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs

Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.

Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Topics

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel